News
BDRX
1.010
-9.01%
-0.100
Weekly Report: what happened at BDRX last week (0429-0503)?
Weekly Report · 1d ago
Biodexa’s eRapa Shows Promise for FAP Treatment
TipRanks · 04/30 17:57
Biodexa's Licensor Emtora To Announce Phase 2 Clinical Trial Results Of eRapa In Familial Adenomatous Polyposis To Be Presented At Prestigious 2024 Digestive Disease Week Annual Meeting
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting in Washington DC. Results of a Phase 2 clinical trial of erapa in Fam familial Adenom atous polyposis are to be presented at the meeting. E rapa is a proprietary oral tablet formulation of rapamycin.
Benzinga · 04/30 15:53
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals among healthcare movers
Seeking Alpha · 04/30 14:01
NIVF, BDRX and ZAPP among pre-market losers
Seeking Alpha · 04/30 12:24
ALT, CYCC and DB among pre-market losers
On the Move ALT, CYCC and DB among pre-market losers. Clever Leaves Holdings (CLVR) announces Voluntary Delisting and SEC Deregistration. Addex Therapeutics Ltd (ADXN) provides update on phase 2 Epilepsy study.
Seeking Alpha · 04/29 12:17
12 Health Care Stocks Moving In Monday's Pre-Market Session
Deciphera Pharmaceuticals (NASDAQ:DCPH) stock rose 71.0% to $25.05 during Monday's pre-market session. Koninklijke Philips (NYSE:PHG) shares moved upwards by 40.91%. The company's, Q1 earnings came out today. Akanda and XTL Biopharmaceuticals were the biggest gainers in the market.
Benzinga · 04/29 12:06
Why Is Inno (INHD) Stock Up 46% Today?
More than 8.7 million shares of INHD stock changing hands as of Monday morning. Inno stock is up 46.4% this morning but is down 54.8% year-to-date. The company’s low trading volume and penny stock status could be a concern for investors. The biggest pre-market stock market news traders need to know about on Monday is about Biodexa.
Investorplace · 04/29 11:59
Weekly Report: what happened at BDRX last week (0422-0426)?
Weekly Report · 04/29 11:32
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Shares of Koninklijke Philips N.V. Rose sharply in today's pre-market trading after reporting first-quarter results. The company's shares jumped 37.1% to $28.87. Tesla, Inc. Shares gained 7.3% in pre- market trading. Inno Holdings and Ryde Group were among the other stocks moving in premarket trading.
Benzinga · 04/29 09:53
Why Is Biodexa (BDRX) Up 70% Today?
Biodexa inked a deal with Rapamycin Holdings for rights to a therapeutic called eRapa. The drug targets a disease called Familial Adenomatous Polyposis (FAP) BDRX stock is down 54% year-to-date. The only analyst that covers the company has a "buy" rating on the stock.
Investorplace · 04/26 19:18
Dow Surges Over 200 Points; Microsoft Shares Gain Following Upbeat Earnings
U.S. Stocks traded higher toward the end of trading on Friday. The Dow Jones index gained more than 200 points. Microsoft Corp. Shares rose more than 2% after posting better-than-expected quarterly results. Snap Inc. Shares surged 26% after the company reported better- than-expected first-quarter results. Asian markets closed mostly higher on Friday while European shares were higher.
Benzinga · 04/26 18:50
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Aon plc shares fell 7.4% to $283.19 on Friday. The company reported worse-than-expected quarterly financial results. Biodexa Pharmaceuticals Plc shares jumped 73.3% after the company signed a deal with eRapa. Snap Inc. Shares jumped 23% in the mid-day session.
Benzinga · 04/26 17:56
12 Health Care Stocks Moving In Friday's Intraday Session
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $4.4 billion. Zura Bio, Cullinan Therapeutics and Agenus were the biggest gainers during the session.
Benzinga · 04/26 16:31
S&P 500 Gains 1%; Exxon Mobil Posts Downbeat Earnings
U.S. Stocks traded higher midway through trading on Friday. The Dow traded up 0.41% and the S&P 500 gained around 1%. Exxon Mobil Corporation reported downbeat earnings for its first quarter. Asian markets closed mostly higher on Friday; European shares were also higher.
Benzinga · 04/26 16:06
Biodexa Pharmaceuticals Seals Deal with Emtora Biosciences
TipRanks · 04/26 13:58
Biodexa shares rally 126% on rapamycin licensing deal
Shares of Biodexa Pharmaceuticals soar 126% on rapamycin licensing deal. The company has entered into an exclusive worldwide license to develop and commercialize eRapa, also known as rapamyin. The rights come with $17M for a pivotal study of the drug in the treatment of an orphan disease.
Seeking Alpha · 04/26 13:56
US Stocks Higher Following PCE Inflation Data; Nasdaq Jumps Over 200 Points
Federal Reserve's preferred measure of inflation rose more than expected in March. The Dow traded up 0.20% and the Nasdaq Composite rose 1.36% on Friday. Energy shares dipped by 1.2% as the S&P 500 fell 0.73%. Asian markets closed mostly higher on Friday; European shares were also higher.
Benzinga · 04/26 13:54
Biodexa Enters Into Exclusive License To eRapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP
Biodexa Pharmaceuticals PLC Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP. An estimated 100,000 in U.S. And Europe are afflicted with FAP, precancerous polyps.
Benzinga · 04/26 12:34
More
Webull provides a variety of real-time BDRX stock news. You can receive the latest news about Biodexa Pharmaceuticals plc through multiple platforms. This information may help you make smarter investment decisions.
About BDRX
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.